Multiparametric Prostate MRI Ordering and Performance
In a male patient over 50 with elevated PSA and abnormal DRE, multiparametric prostate MRI should be ordered BEFORE proceeding to biopsy, as this approach detects more clinically significant prostate cancer while reducing unnecessary biopsies and overdiagnosis of indolent disease. 1
Pre-MRI Considerations
Before ordering the MRI, confirm the PSA elevation after a few weeks under standardized conditions (no ejaculation, prostate manipulations, or urinary tract infections) in the same laboratory 1. Calculate PSA density (PSA-D = serum PSA ÷ prostate volume) using a cut-off of 0.15 ng/ml/cc, as this is one of the strongest predictors of clinically significant prostate cancer 1.
MRI Protocol Specifications
Order a multiparametric MRI (mpMRI) using the PI-RADS v2 reporting system, which should include:
- High-resolution T2-weighted imaging
- Diffusion-weighted imaging (DWI) with apparent diffusion coefficient (ADC) mapping
- Dynamic contrast-enhanced (DCE) imaging when available 2
The examination must be performed by robustly trained radiologists working within multidisciplinary teams, as test performance depends critically on imaging quality 2. The PI-RADS v2 system has demonstrated higher accuracy than systematic TRUS biopsies for prostate cancer diagnosis and successfully detects the majority of tumors capable of causing patient harm 2.
Interpreting Results and Next Steps
Risk Stratification Based on PI-RADS Score and PSA-D
Use this evidence-based matrix to determine biopsy indication 1:
PI-RADS 1-2 with PSA-D <0.10 ng/ml: Very low risk - consider avoiding biopsy
PI-RADS 3 with PSA-D 0.10-0.15 ng/ml: Intermediate risk - shared decision-making regarding biopsy
PI-RADS 4-5 with PSA-D 0.15-0.20 ng/ml: High risk - proceed to targeted biopsy
PI-RADS 4-5 with PSA-D >0.20 ng/ml: Very high risk - proceed to targeted biopsy
Biopsy Approach When MRI is Positive
When mpMRI identifies suspicious lesions (PI-RADS ≥3), perform MRI-targeted biopsy PLUS systematic perilesional biopsy 1. This combined approach is superior to either method alone. The targeted component should focus on the index lesion identified on MRI, while systematic sampling captures potential multifocal disease.
Performance Characteristics
MpMRI demonstrates pooled sensitivity of 0.91 (95% CI: 0.83-0.95) and specificity of 0.37 (95% CI: 0.29-0.46) for ISUP grade 2 cancers, with even better performance for ISUP grade 3 cancers: sensitivity 0.95 (95% CI: 0.87-0.99) 1.
Critical caveat: While mpMRI significantly improves detection of clinically significant disease, it does not detect all cancers. However, it successfully identifies the majority of tumors capable of causing patient harm while reducing detection of clinically insignificant disease that would not benefit from treatment 2.
When MRI is Negative (PI-RADS 1-2)
In biopsy-naïve men with negative or low-suspicion MRI and PSA-D <0.15 ng/ml/cc, consider avoiding immediate biopsy and implementing surveillance with repeat PSA testing 1. The negative predictive value of mpMRI is high, particularly when combined with low PSA-D.
Quality Assurance Requirements
Success of this diagnostic pathway requires:
- High-quality imaging acquisition and reporting
- Radiologists trained specifically in prostate MRI interpretation using PI-RADS v2
- Urologists experienced in MRI-targeted biopsy techniques
- Joint working within multidisciplinary teams 2
Poor quality MRI or inadequate radiologist training significantly compromises diagnostic accuracy and can lead to both false-positive and false-negative results.